After 72 hr of drug exposure, the cells were stained with fluorescently labeled antibodies against a panel of AML-related cell surface markers (CD45, CD34, CD38, CD117, HLA-DR, CD45-RA, CD3 and a mix of myeloid differentiation-related markers). The gene discussed is KIT; the disease is acute myeloid leukemia.